Teleflex

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The firm designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teleflex reports Q4 growth amidst challenges, eyes revenue acceleration

Teleflex's Q4 performance showed resilience with revenue growth and strategic acquisitions. While facing challenges like supply chain disruptions and UroLift revenue decline, the company is focused on margin expansion and disciplined growth. Opportunities lie in revenue acceleration, international expansion, and leveraging high-growth product categories.

Teleflex reports robust Q1 earnings, eyes growth amid challenges

Teleflex's Q1 2023 results reflect strong performance and strategic focus on sustainable growth, supported by geographic revenue growth and product category contributions.
While facing challenges in specific product lines and supply chain issues, the company maintains a disciplined approach to deals and cost management.
Opportunities lie in revised revenue guidance, product performance, and market improvements, positioning Teleflex for continued success in 2023.

Teleflex reports revenue growth and strategic acquisitions drive future outlook

Teleflex revised its 2023 financial guidance with revenue growth of 5.5% to 6.25% and adjusted EPS of $13 to $13.60. Despite challenges in certain product segments, the company remains confident in achieving its Long Range Plan growth objectives. The focus on integrating acquisitions like Palette and leveraging high-growth products positions Teleflex for continued success.

Teleflex reports robust Q3 results, eyes growth amidst challenges

Teleflex's Q3 performance reflects revenue and EPS growth, driven by operational improvements.
Despite challenges from GLP-1 impact and tax rate increases, the company remains optimistic.
Opportunities lie in market expansion, M&A activities, and product uniqueness strategies.
Overall, Teleflex's strong financials and strategic initiatives position it for continued growth.

Teleflex reports solid 2023 performance, eyes growth in Urology market

Teleflex's 2023 performance showed revenue growth and strong cash flow, with guidance for 2024 indicating continued growth and margin targets.
Despite challenges like declining EPS and recall impacts, the company aims for high EPS growth and sees opportunities in new markets and product expansions.
Confidence in meeting targets, pursuing strategic initiatives, and navigating market challenges position Teleflex for growth and profitability in the coming years.
Balancing financial performance with strategic investments and operational improvements will be key for Teleflex to capitalize on growth opportunities and overcome challenges.

Teleflex reports solid Q1 performance, eyes growth through acquisitions

Teleflex's Q1 2024 performance was solid, with revenue growth, margin expansion, and strong cash flow. Despite challenges like market multiples and recall impacts, the company is focused on growth opportunities and disciplined acquisitions to drive future success.

Teleflex reports solid Q2 growth, eyes M&A and product innovation

Teleflex's Q2 performance reflects steady growth, driven by strong results in key segments and product categories.
Despite challenges in certain areas, the company's strategic initiatives, including acquisitions and product innovation, position it well for future success.
With a focus on revenue growth, operational efficiency, and shareholder value, Teleflex is poised to capitalize on opportunities and navigate challenges effectively.

Teleflex reports solid Q3 earnings, eyes growth amid challenges

Teleflex's Q3 2024 performance showcased revenue growth, margin improvement, and strategic acquisitions driving increased revenue guidance for the year.
While facing challenges in specific product categories, the company's focus on innovation, market expansion, and financial strength positions it well for future growth.
Opportunities in expanding markets, disciplined capital allocation, and strong cash flow generation underscore Teleflex's resilience and potential for sustained success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teleflex, Inc. provides medical technology products which enable healthcare providers to improve patient outcomes and enhance patient and provider safety. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The company was founded in 1943 and is headquartered in Wayne, PA.

New Findings Show UroLift System Same-Day Outpatient Procedure Demonstrates Symptom Improvement for Benign Prostatic Hyperplasia New Findings Show UroLift System Same-Day Outpatient Procedure Demonstrates Symptom Improvement for Benign Prostatic Hyperplasia

Research Reinforcing the Effectiveness and Safety of the UroLift® System in the Real-World Setting Presented at 50th Annual ICS Meeting

Teleflex (TFX) expects further adverse financial impact of the coronavirus pandemic.

Teleflex (TFX) Hurt by COVID-19-Led Disruption, UroLift Grows

Teleflex (TFX) witnesses significant sequential improvement in segmental performance on gradual recovery of the economy.

Teleflex (TFX) Q3 Earnings & Revenues Beat, Decline Y/Y

WAYNE, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Stephens Investment Conference 2020, on Monday, November 16, 2020 at 1:00 p.m. (ET).

Teleflex to Present at the Stephens Investment Conference 2020

Teleflex Incorporated (TFX) CEO Liam Kelly on Q3 2020 Results - Earnings Call Transcript

 Shares of Teleflex (NYSE:TFX) rose 0.1% in pre-market trading after the company reported Q3 results.

Recap: Teleflex Q3 Earnings

Third Quarter Revenues of $628.3 million, down 3.1% versus Prior Year Period on an As-Reported basis; down 4.1% on a Constant Currency basis

Teleflex Reports Third Quarter 2020 Results

Signs Definitive Agreement to Acquire Linden Capital's Z-Medica Signs Definitive Agreement to Acquire Linden Capital's Z-Medica

Teleflex to Acquire Market Leader in Hemostatic Products

WAYNE, Pa., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the expansion of its UroLift® System portfolio with the introduction of the UroLift® Advanced Tissue Control (ATC)™ System. The new system, which builds on the highly successful UroLift System, features a number of enhancements to enable urologists to more easily treat benign prostatic hyperplasia (BPH) patients with challenging anatomies, including an obstructive median lobe and large lateral lobes. The UroLift ATC System will be launched on a limited basis while the business unit expands its capacity to meet demand.

Teleflex Interventional Urology Expands Portfolio with Introduction of the UroLift® Advanced Tissue Control (ATC)™ System

Most important CVC update in a decade adds a variety of clinician-inspired enhancements Most important CVC update in a decade adds a variety of clinician-inspired enhancements

Teleflex Delivers COMPLETE Confidence with the New Arrow® ErgoPack® Complete CVC System

Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, October 29, 2020 Live Webcast is scheduled at 8:00 a.m. (ET) on Thursday, October 29, 2020

Teleflex Announces Third Quarter 2020 Earnings Conference Call Information

Teleflex stock gained around 10% over the month to levels of around $362 currently. But will the company’s stock see higher prices over the coming weeks, or is a decline in the stock imminent?

What’s Next For Teleflex Stock After 10% Gain In A Month

Company ranks as a top employer in the state of Pennsylvania where its corporate headquarters are located Company ranks as a top employer in the state of Pennsylvania where its corporate headquarters are located

Teleflex Named One of America’s Best-In-State Employers 2020 by Forbes

Teleflex's (TFX) recent expanded indications for its IO device provide more time to physicians to establish safe vascular access.

Teleflex's (TFX) Arrow EZ-IO Gets FDA's Expanded Indications

Now Cleared for up to 48-Hour Dwell Now Cleared for up to 48-Hour Dwell

Teleflex Announces Expanded Indications for the Arrow® EZ-IO® Intraosseous Vascular Access System

WAYNE, Pa., Sept.  02, 2020  (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 2:00 p.m. (ET). 

Teleflex to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Teleflex (TFX) reported earnings 30 days ago. What's next for the stock?

How Has TFX Performed 30 Days Post Earnings

WAYNE, Pa., Aug.  26, 2020  (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the Wells Fargo 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 12:40 p.m. (ET). 

Teleflex to Present at the Wells Fargo 2020 Virtual Healthcare Conference

The acquired business of Teleflex (TFX), NeoTract has been performing impressively lately.

TeleFlex Banks on Urolift Sales Amid Coronavirus-Led Debacle

The annual report highlights how Teleflex is driving the shift towards a sustainable future through its employee-led JOIN Act with Purpose CSR initiative The annual report highlights how Teleflex is driving the shift towards a sustainable future through its employee-led JOIN Act with Purpose CSR initiative

Teleflex Publishes 2nd Annual Global JOIN Impact Report

Teleflex Incorporated (TFX) CEO Liam Kelly on Q2 2020 Results - Earnings Call Transcript

Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.

Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract

Teleflex (TFX) delivered earnings and revenue surprises of 55.65% and 6.46%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Teleflex (TFX) Q2 Earnings and Revenues Surpass Estimates

Minimally Invasive, Same-Day Outpatient Procedure Provides Rapid Symptom Relief and Recovery Minimally Invasive, Same-Day Outpatient Procedure Provides Rapid Symptom Relief and Recovery

Teleflex Announces 200,000 Patients Treated with UroLift System for Enlarged Prostate

Baxter

Bio-Rad Laboratories

QuidelOrtho Corp

Stryker

Despite the impact of the pandemic on the second quarter, Medical Product companies have shown strength on the back of huge adoption of COVID-19 related healthcare-support products and services.

News for Teleflex Stock (TFX)